New Study Identifies Leukotriene B4 as a Target for Lymphedema Treatment

Understanding Acquired Lymphedema

Acquired lymphedema is a significant global health issue, affecting approximately 15-50% of cancer survivors and an estimated 90 million individuals worldwide. This condition is characterized by fluid retention and swelling, resulting from impaired lymphatic flow due to structural damage to lymphatic vessels. Secondary lymphedema, also known as acquired lymphedema, arises from damage to lymphatic vessels caused by factors such as parasitic infections, lymph node resection, or radiotherapy in cancer patients.

Current Treatment Limitations

Presently, treatment options for lymphedema are largely temporary, with limited pharmacotherapeutic alternatives available. Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), is often used to manage lymphedema; however, it is associated with various side effects, including gastrointestinal, cardiac, nervous system, renal, and hepatic toxicities, which limit its long-term use.

Breakthrough Research Findings

A recent study published in *Science Translational Medicine* has identified leukotriene B4 (LTB4) as a new pharmacological target for lymphedema treatment. Researchers found that administering LTB4-blocking drugs, such as ketoprofen, bestatin, and zileuton, to mice with lymphedema resulted in a reduction of the condition.

The study revealed that LTB4 exhibits bimodal effects: low concentrations (2nM-10nM) of LTB4 promote lymphomagenesis, whereas high concentrations (400nM) inhibit the formation of lymphatic vessels and disrupt lymphatic circulation. During the progression of lymphedema, LTB4 levels increase from low to high concentrations, ultimately leading to the destruction of lymphatic vessels.

Interestingly, the research indicated that low concentrations of LTB4 enhance the expression of lymphomagenesis-related genes, such as VEGFR and Notch1, while high concentrations exert an inhibitory effect.

Implications for Future Treatment

The findings suggest that LTB4 represents a promising drug target for the treatment of acquired lymphedema, which is a serious and progressive disease currently lacking effective pharmacologic therapies. While ketoprofen remains the most viable treatment option at present, this new research indicates the potential for more effective alternative treatments in the future.

Conclusion

The identification of LTB4 as a target for lymphedema treatment marks a significant advancement in the search for effective therapies for this challenging condition.

Written By: Boram Ham, PhD
Add to Flipboard Magazine.